85 results about "Collagen ADP" patented technology

Disclosed are bilayer matrices of a polysaccharide such as collagen (COL) and another polysaccharide such as hyaluronic acid (HA) with various COL/HA ratios. Each layer has a porous structure. These materials are useful for tissue regeneration, particularly when used with orthopedic implants and drug delivery.

The invention provides a class of samples that model the human body. This family of samples is based upon emulsions of oil in water with lecithin acting as the emulsifier. These solutions that have varying particle sizes may be spiked with basis set components (albumin, urea and glucose) to simulate skin tissues further. The family of samples is such that other organic compounds such as collagen, elastin, globulin and bilirubin may be added, as can salts such as Na+, K+ and Cl-. Layers of varying thickness with known index of refraction and particle size distributions may be generated using simple crosslinking reagents, such as collagen (gelatin). The resulting samples are flexible in each analyte's concentration and match the skin layers of the body in terms of the samples reduced scattering and absorption coefficients, mums and muma. This family of samples is provided for use in the medical field where lasers and spectroscopy based analyzers are used in treatment of the body. In particular, knowledge may be gained on net analyte signal, photon depth of penetration, photon radial diffusion, photon interaction between tissue layers, photon density (all as a function of frequency) and on instrument parameter specifications such as resolution and required dynamic range (A/D bits required). In particular, applications to delineate such parameters have been developed for the application of noninvasive glucose determination in the near-IR region from 700 to 2500 nm with an emphasis on the region 1000 to 2500 nm (10,000 to 4,000 cm-1).

A cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1 and uses thereof for stem cell delivery.

A collagen matrix material is charged with a cell growth-promoting derived nucleic acid sequence. The nucleic acid sequence-charged collagen matrix material may be utilized in a method of promoting regeneration of surface cartilage of a joint. In the method, an area of injury is covered with the nucleic acid sequence-charged collagen matrix material, the collagen matrix material is fixed over the area to be treated, and the area is allowed to heal.

The invention is based on selective inhibition of the enzyme (MMP-1), which causes the dermal matrix damage in humans, while sparing the enzyme(s) (MMP-9 and perhaps MMP-2) which not only do not cause the damage (based on extrapolation from our in vitro collagen gel system to real skin) but actually "clear away" the damage produced by MMP-1 to restore normal function to the skin. Matrix metalloproteinase-1 (MMP-1; fibroblast collagenase) is induced by UV radiation from the sun and is naturally elevated in old age. Human fibroblasts exposed to the degradation products of MMP-1 contract collagen, but when this debris is removed from their environment, the fibroblasts behave normally. Inhibiting MMP-1 but sparing enzymes that remove the debris improves human skin after onslaught from solar UV radiation, old age, and acne.

The present invention relates to a solid composition useful for tissue gluing, tissue sealing and haemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N/cm, density of 1-10 mg/cm3, chamber diameter of more than 0.75 mm and less than 4 mm and/or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin. The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibres. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and/or thrombin. In a preferred embodiment the composition does not comprise any antifibronolytic agent such as aprotinin, epsi-aminocaproic acid or alpha2-antiplasmin,

This invention relates to a method of fabricating collagen-based hydrogels loaded with ZnO QDs/pDNA complexes as corneal substitutes. Polycation-modified ZnO Quantum Dots were encapsulated into IPN hydrogels by the adsorption effect of freeze-dried hydrogels. The weight ratio of substitutes and ZnO QDs complex is approximately 425:1. And the weight ratio of ZnO QDs/pDNA is 25:1. This kind of corneal substitutes possess favorable biocompatibility. It is able to induce and promote the regeneration of the cornea and it will degrade along with the regeneration of the cornea. The incorporation of the MPDSAH can enhance the stability of corneal substitutes under the existence of collagenase. ZnO QDs used in this invention can condense DNA effectively and ferry DNA into cells successfully. In the process of transfection, the location and distribution of DNA/vector can be tracked by fluorescence in real time. What's more, the convenience of preparation, long term storage and transportation offers a general method to fabricate a promising corneal substitute.

The invention discloses a method for preparing a basic fibroblast growth factor (bFGF) sustained-release carrier, which comprises the following steps of: 1, preparing bFGF-poly(lactide-co-glycolide) (PLGA) sustained-release microspheres encapsulating 0.00001 to 0.001 percent of bFGF; 2, dissolving type I collagen in an acetic acid solution to obtain a collagen solution; 3, mixing and stirring the bFGF-PLGA sustained-release microspheres and the collagen solution, performing freeze drying, solidifying, and performing freeze drying again to obtain a bFGF-PLGA collagen sustained-release carrier; and 4, performing in-vitro release experiments and Balb/c3T3 cell proliferation promotion experiments, wherein experimental results show that the sustained-release carrier has good biocompatibility, can slowly control the release of the bFGF and effectively promote Balb/c3T3 cell growth, and is an ideal bFGF sustained-release carrier.

A bio-mimetic or bio-implantable material based on a sequential process of coupling biomolecule layers to a polymer layer is provided. In general, the material could be based on two or more biomolecule layers starting with one of the layers covalently linked to the polymer layer via cross-linkers and the other layers sequentially and covalently linked using cross-linkers to the previously added layer. The polymer layer could be a hydrogel or an interpenetrating polymer network hydrogel. The first layer of biomolecules could be a collagen type, fibronectin, laminin, extracellular matrix protein, or any combinations thereof. The second layer of biomolecules typically is a growth factor, protein or stimulant. The cross-linkers are either water soluble or insoluble bifunctional cross-linkers or azide-active-ester crosslinkers. The material and process as taught in this invention are useful in the field of tissue engineering and wound healing.

A process for producing a collagen/hydroxyapatite (HA) composite scaffold comprises the steps of forming a homogenous suspension of collagen and HA in an acidic solution, lyophilising the suspension until a desired final freezing temperature is reached to produce the composite scaffold, and optionally cross-linking the composite scaffold, wherein the ratio of HA to collagen is at least 1:10 (w/w). Also provided is a collagen/hydroxyapatite (HA) composite scaffold comprising a homogenous distribution of hydroxyapatite within a porous, crosslinked, collagen matrix, wherein the ratio of HA to collagen is at least 1:10 (w/w). Suitably, the composite scaffold has a porosity of at least 99% (v/v), and a compressive stiffness of at least 0.3 KPa. Composite scaffolds of the invention may be used to provide osteoconductive bone implants and tissue engineering implants.

The embodiment of the invention discloses an autologous collagen-containing water needle and a preparation method thereof. The autologous collagen-containing water needle comprises the following components in parts by weight: 10-20 parts of autologous collagen, 10-20 parts of hyaluronic acid, 5-10 parts of biopolysaccharide glue, 5-10 parts of a sheep placenta extract, 3-8 parts of a levorotatoryC stock solution, 2-3 parts of a grape seed extract, 2-5 parts of fructan, 2-5 parts of beta-glucan, 1-5 parts of vitamin C, 2-5 parts of amino acid, 2-3 parts of an coenzyme, 2-4 parts of an anti-allergic agent, 2-5 parts of an antioxidant, 1-3 parts of a sun-screening agent and 3-8 parts of a moisturizer. The water needle is prepared from the autologous collagen extracted from human venous blood, is autologous, does not generate exclusion, contains a variety of nutrients required for cell repair and cell growth, and has relatively strong efficacies of accelerating wound healing of skin and mucosa, promoting the cell growth, promoting wound healing and strengthening the immune system.

The invention discloses a preparation for promoting fibroblasts to secrete extracellular matrix components, and a preparation method and application thereof. The preparation comprises the components of A) the egg white of eggs, B) egg white lysozyme, and C) pyruvic acid or pyruvate, can also comprise ovotransferrin and/or glucose, and is obtained by mixing the components uniformly. The preparationcan serve as an externally used paste for skin in application, and can obviously stimulate the secretion of collagen and hyaluronic acid synthase in the fibroblasts of the skin and improve the resiliency and the moisture content of the skin. The preparation is derived from a biologic extractive technique, has no harmful substance residues, safe and high-efficiency use, and is different from the prior method for promoting the secretion of a single fibroblast ECM component; besides, the preparation has multiple effects, wide application range and extensive application prospect, and can be applied in the fields of the preparation of skin substitutes, the preparation of anti-aging skin care products, cosmetics, medical treatment and the like.

Provided is a collagen-cellulose material containing, based on a total weight of the collagen-cellulose material: 1.0-9.0 wt. % of a collagen; 0.2-3.0 wt. % of cellulose or a derivative thereof; 0.5-6.5 wt. % of at least one acid selected from an inorganic acid, an organic acid, and mixtures thereof; and water. Also provided is a process for producing the collagen-cellulose material. Also provided is an artificial blood vessel containing the collagen-cellulose material which is in the form of a hollow tube, an artificial tissue containing the collagen-cellulose material which is in the form of a sheet, and an artificial bone containing the collagen-cellulose material which is in the form of a solid. Also provided is a medical device containing the collagen-cellulose material, as well as a process for testing phlebotomical, surgical or orthopedic instrumentation or practicing phlebotomical, surgical or orthopedic procedures using the medical device containing the collagen-cellulose material.

The present invention relates to a tissue sealant in which collagen and fibrin are mixed and to a method for preparing same. To this end, the method of the present invention comprises the steps of: mixing a first material using fibrinogen and aprotinin; mixing a second material using thrombin, calcium chloride, and collagen; and preparing a third material by mixing the first material and the second material. The tissue sealant prepared by the method may supplement weaknesses, i.e. strength and degradability, of the fibrin sealant which is currently available in the commercial marketplace. Further, the tissue sealant of the present invention is cytophilic and activates blood platelets contained in blood so as to induce tissue regeneration. Thus, quality and reliability of products can be significantly improved so as to satisfy various needs of consumers who are users, thereby presenting good image.

A composition for application to the skin can stimulate the in vivo synthesis of collagen and proteoglycans and improve the appearance of the skin, increasing its elasticity and fullness. In general, a composition according to the present invention comprises: (1) an antioxidant compound in a quantity sufficient to enhance collagen synthesis in the skin; (2) an organic penetrant in which the antioxidant compound is soluble in a sufficient quantity that a concentration of the antioxidant compound sufficient to enhance collagen synthesis can be applied topically and penetrate the skin; (3) a mixture of essential amino acids or hydrolyzed whey protein; (4) a supplemental source of sulfur; and (5) a topical pharmaceutically acceptable carrier. The antioxidant compound can be lipoic acid or a lipoic acid analogue or derivative. The organic penetrant is preferably benzyl alcohol. Other ingredients, such as esters of tocopherol and ascorbic acid, can be included.

This disclosure provides a method of determining the viability of at least one cell via quantification of nicotinamide adenine dinucleotide (phosphate) (NAD(P)H), flavin adenine dinucleotide (FAD), and/or collagen. The method includes the steps of contacting the at least one cell with light having a wavelength of from 700 to 900 nm, using two photon excitation, or from 335 to 400 nm, using one photon excitation, to induce an optical response from the NAD(P)H, FAD, and/or collagen and measuring the optical response. The method also includes the step of quantifying one or more of an amount, spatial localization, and/or time-dependent response of the NAD(P)H, FAD, and/or collagen utilizing the optical response.

The invention discloses an anti-glycation facial mask which comprises a mask base fabric (1) and a mask essence (2), wherein the mask essence comprises a water-soluble thickener (a), 0.1-20 wt% of a moisturizer (b), 0.1-10 wt% of an anti-glycation composition (c) and a water-bearing carrier (d); by using the water-soluble thickener, the mask essence has the viscosity of 1-10000 mPa.s; the moisturizer comprises polylol and sodium hyaluronate; and the anti-glycation composition comprises a pea extract and an Argania spinosa leaf extract. The anti-glycation facial mask can effectively inhibit the activities of metal proteinase and collagenase, promotes the synthesis of collagen, glycosaminoglycans (GAGs) and elastin, enables the skin to be tight and elastic and have fewer wrinkles, and thus, has favorable antiaging effects.